ADI-PEG 20 (pegargiminase)
Malignant Pleural Mesothelioma
Key Facts
About Polaris Pharma
Polaris Pharma is a clinical-stage biotech advancing its lead asset, ADI-PEG 20, a pegylated arginine deiminase enzyme designed to starve ASS1-deficient cancers of arginine. The company has a diversified late-stage pipeline, with its most advanced program in malignant pleural mesothelioma under FDA review (BLA submission) and several other Phase 2/3 trials ongoing. With integrated cGMP manufacturing capabilities and orphan drug designations for key indications, Polaris is positioning itself as a player in metabolic cancer therapy, though it faces significant clinical and regulatory execution risks.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech advancing its lead asset, ADI-PEG 20, a pegylated arginine deiminase enzyme designed to starve ASS1-deficient cancers of arginine. The company has a diversified late-stage pipeline, with its most advanced program in malignant pleural mesothelioma under FDA review (BLA submission) and several other Phase 2/3 trials ongoing. With integrated cGMP manufacturing capabilities and orphan drug designations for key indications, Polaris is positioning itself as a player in metabolic cancer therapy, though it faces significant clinical and regulatory execution risks.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech advancing its lead asset, ADI-PEG 20, a pegylated arginine deiminase enzyme designed to starve ASS1-deficient cancers of arginine. The company has a diversified late-stage pipeline, with its most advanced program in malignant pleural mesothelioma under FDA review (BLA submission) and several other Phase 2/3 trials ongoing. With integrated cGMP manufacturing capabilities and orphan drug designations for key indications, Polaris is positioning itself as a player in metabolic cancer therapy, though it faces significant clinical and regulatory execution risks.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech advancing its lead asset, ADI-PEG 20, a pegylated arginine deiminase enzyme designed to starve ASS1-deficient cancers of arginine. The company has a diversified late-stage pipeline, with its most advanced program in malignant pleural mesothelioma under FDA review (BLA submission) and several other Phase 2/3 trials ongoing. With integrated cGMP manufacturing capabilities and orphan drug designations for key indications, Polaris is positioning itself as a player in metabolic cancer therapy, though it faces significant clinical and regulatory execution risks.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech advancing its lead asset, ADI-PEG 20, a pegylated arginine deiminase enzyme designed to starve ASS1-deficient cancers of arginine. The company has a diversified late-stage pipeline, with its most advanced program in malignant pleural mesothelioma under FDA review (BLA submission) and several other Phase 2/3 trials ongoing. With integrated cGMP manufacturing capabilities and orphan drug designations for key indications, Polaris is positioning itself as a player in metabolic cancer therapy, though it faces significant clinical and regulatory execution risks.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech advancing its lead asset, ADI-PEG 20, a pegylated arginine deiminase enzyme designed to starve ASS1-deficient cancers of arginine. The company has a diversified late-stage pipeline, with its most advanced program in malignant pleural mesothelioma under FDA review (BLA submission) and several other Phase 2/3 trials ongoing. With integrated cGMP manufacturing capabilities and orphan drug designations for key indications, Polaris is positioning itself as a player in metabolic cancer therapy, though it faces significant clinical and regulatory execution risks.
View full company profileTherapeutic Areas
Other Malignant Pleural Mesothelioma Drugs
| Drug | Company | Phase |
|---|---|---|
| Dosie™ for I-PDT | Simphotek | Pre-clinical/Development |
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2 |
| Radspherin | Oncoinvent | Preclinical |